We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App




Medix Biochemica Launches Refreshed and Expanding Brand to Reflect Growing IVD Products Portfolio

By LabMedica International staff writers
Posted on 04 Mar 2022
Print article
Image: Medix Biochemica introduces its refreshed and expanding brand (Photo courtesy of Medix Biochemica)
Image: Medix Biochemica introduces its refreshed and expanding brand (Photo courtesy of Medix Biochemica)

Medix Biochemica (Finland) is launching a rejuvenated brand to reflect both the improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry. The company hopes that its accelerated growth will establish its status as the ultimate IVD raw materials supplier. A new website brings to life a brand-new creative campaign that communicates every aspect of Medix’s expertise – alongside an aspirational corporate identity to reflect the company’s ambitions.

In line with its commitment to offering its customers the most comprehensive IVD raw materials portfolio in the business, Medix has acquired several companies, each with their own expertise across the IVD market. In 2019, Lee Biosolutions was acquired, followed by EastCoast Bio and Biostride in 2020, Diaclone just last year and, most recently, myPOLS Biotec GmbH, which will strengthen its existing molecular diagnostics division, MedixMDx. This integration has helped Medix broaden its portfolio to over 5,000 products in categories such as molecular reagents, enzymes, biospecimens and immunoreagents.

Based on customer feedback and its aim to create a better business for its customers, has launched brand new website that will be the go-to place for its customers. Whether it’s a streamlined product experience or a specific service such as antibody, DNA or RNA polymerase engineering, customers will be able to find out more and contact the company directly to discuss their needs. The launch is another step towards Medix’s vision to be the first-choice, independent raw material partner for the IVD industry.

“The launch of the new Medix Biochemica brand is the culmination of years of hard work,” said Steve Ferguson, CEO of Medix Biochemica. “We are so excited to be able to offer our customers more services, more expertise, more product choices than ever before. And most importantly, still with the same quality and care our customers are used to receiving from Medix Biochemica.”

Related Links:
Medix Biochemica

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.